Is sarcopenia effective on survival in patients with metastatic gastric cancer?

doi:10.4251/wjgo.v16.i5.1861

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1426)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

HTML

817

Figures (1-2)

168

Tables (1-2)

157

Sum=1184

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

169

Sum=198

May 15, 2024 (publication date) through Jan 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. May 15, 2024; 16(5): 1861-1868
Published online May 15, 2024. doi: 10.4251/wjgo.v16.i5.1861

Table 1 Clinicopathologic characteristics of patients, n (%)

Patient characteristics	Sarcopenic	Non-sarcopenic	P value
Sex
Female	7 (24.1)	21 (23.6)	0.567
Male	22 (75.9)	68 (76.4)	N/A
Age in yr
< 65	12 (41.4)	48 (53.9)	0.288
≥ 65	17 (58.6)	41 (46.1)	N/A
PS score in points			0.197
0 or 1	19 (65.5)	69 (77.5)	N/A
2 or 3	10 (34.5)	20 (22.5)	N/A
Differentiation			0.823
Moderate or well	11 (44.0)	29 (41.4)	N/A
Poor	14 (56.0)	41 (58.6)	N/A
Smoking history			0.193
Yes	19 (65.5)	46 (51.7)	N/A
No	10 (34.5)	43 (48.3)	N/A
Number of metastatic sites			0.513
< 2	19 (65.5)	64 (71.9)	N/A
≥ 2	10 (34.5)	25 (28.1)	N/A
CEA level			0.295
< 5	10 (35.7)	40 (47.1)	N/A
≥ 5	18 (64.3)	45 (52.9)	N/A
BMI in kg/m²			0.427
Underweight, < 18.5	1 (3.4)	10 (11.2)	N/A
Normal, 18.5-24.9	18 (62.1)	47 (52.8)	N/A
Overweight, 25.0-29.9	7 (24.1)	27 (30.3)	N/A
Obese, > 30.0	3 (10.3)	5 (5.6)	N/A

BMI: Body mass index; CEA: Carcinoembryonic antigen; N/A: Not applicable; PS: Performance status.

Table 2 Univariate and multivariate analysis of clinicopathologic characteristics on survival

Clinicopathologic characteristics	Univariate analyses, HR (95%CI)	P value	Multivariate analyses, HR (95%CI)	P value
Age in yr, < 65 vs ≥ 65	1.366 (0.942-1.979)	0.100	N/A	N/A
Sex, female vs male	0.963 (0.776-1.196)	0.735	N/A	N/A
PS score in points, 0 or 1 vs 2 or 3	1.142 (0.745-1.753)	0.542	N/A	N/A
Differentiation, moderate or well vs poor	0.947 (0.622-1.441)	0.800	N/A	N/A
Number of metastases, < 2 vs ≥ 2	1.416 (0.947-2.118)	0.090	N/A	N/A
CEA level, < 5 vs ≥ 5	1.707 (1.144-2.548)	0.009	1.650 (1.102-2.469)	0.015
Smoking history, yes vs no	0.956 (0.794-1.151)	0.634	N/A	N/A
Presence of sarcopenia, yes vs no	9.512 (5.489-16.484)	0.000	9.542 (5.398-16.867)	0.000
BMI in kg/m²: underweight, < 18.5; normal, 18.5-24.9; overweight, 25.0-29.9; obese, > 30.0	0.914 (0.722-1.157)	0.456	N/A	N/A

BMI: Body mass index; CEA: Carcinoembryonic antigen; CI: Confidence interval; N/A: Not applicable; HR: Hazard ratio; PS: Performance status.

Citation: Dogan O, Sahinli H, Duzkopru Y, Akdag T, Kocanoglu A. Is sarcopenia effective on survival in patients with metastatic gastric cancer? World J Gastrointest Oncol 2024; 16(5): 1861-1868
URL: https://www.wjgnet.com/1948-5204/full/v16/i5/1861.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i5.1861